I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR ...
Corvus Pharmaceuticals (CRVS) is in the process of evaluating the use of its interleukin-2-inducible T cell kinase [ITK] inhibitor for the treatment of patients with a wide variety of lymphoma types, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results